<DOC>
	<DOCNO>NCT00491166</DOCNO>
	<brief_summary>This investigator-sponsored trial ( IST ) , open-label pilot study , assess safety biologic activity bromfenac subject diffuse DME refractory laser .</brief_summary>
	<brief_title>Safety Study Bromfenac Ophthalmic Solution Subjects With Diffuse Diabetic Macular Edema ( DME ) Refractory Laser</brief_title>
	<detailed_description>Ten subject enrol study , conduct Ophthalmic Consultants Boston , Boston , MA . All subject must diagnose diffuse DME either refractory laser photocoagulation patient refuse laser . Consented subject screen determine eligibility . Eligibility determine Investigator , retinal specialist . Only one eye choose “ study eye. ” Only study eye receive bromfenac drop study . Eligible subject self-administer bromfenac two time per day ( BID ) three month ( treatment period ) . Subjects monthly examination treatment period , follow follow visit Month 4 Month 6 .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Age &gt; 18 year Centerinvolved macular edema secondary diabetes mellitus Study eye edema amenable focal laser Treatment laser , intraocular steroid , antiVEGF agent within 90 day Current eye infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>bromfenac ophthalmic solution</keyword>
</DOC>